BostonGene and MUSC Partner on CAR-T Research
The research collaboration aims to evaluate immune dynamics in patients undergoing CAR-T therapy for non-Hodgkin lymphoma.
Updated on Oct. 22, 2026 in Biotech
Live Poll
Do you believe integrating AI into clinical cancer research will improve patient treatment outcomes?
BostonGene and the Medical University of South Carolina have launched a research collaboration to study immune system dynamics in CAR-T therapy patients. The partnership focuses on improving clinical outcomes for those with relapsed or refractory CD19 B-cell non-Hodgkin lymphoma.
Why it matters
By identifying biological mechanisms associated with treatment resistance and toxicity, this collaboration seeks to refine patient selection and improve the durability of advanced cancer therapies.
Preliminary phase Ib trial results demonstrated a 67% complete remission rate among participants. The study reported no instances of grade 3+ cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome.
The players
BostonGene
A company that utilizes a biologically grounded AI platform to model complex immune system dynamics for clinical research.
Medical University of South Carolina
A public academic health science center in South Carolina that conducts clinical trials and biomedical research.
The details
Researchers are utilizing a biologically grounded AI platform to integrate multiomics data, including bulk RNA sequencing and high-throughput multi-colour flow cytometry. The team is specifically mapping connections between CD8 effector memory cells and positive treatment responses, while noting that baseline T-cell exhaustion often indicates progressive disease.
Timeline
October 22, 2026: The research collaboration was officially announced.
2026: Preliminary trial data was presented at ASCO.
The Big Picture
This collaboration follows the ASCO clinical trial presentation protocols for reporting immune system metrics in cancer patients. The partnership adheres to these established standards to validate the link between molecular cellular changes and long-term clinical outcomes.
This research could eventually lead to improved screening methods that help clinicians identify which patients are most likely to respond to CAR-T therapy. By predicting potential toxicity in advance, providers may be able to adjust treatment plans to enhance safety and effectiveness.
The takeaway
Advancing the understanding of immune dynamics is essential for improving the precision of modern cancer treatments. Future clinical applications depend on effectively translating molecular biomarker findings into actionable diagnostic tools for physicians.
Further reading
Learn more about the latest developments in Biotech.
Source note: This article includes information reported by Pharmabiz.
Live Poll
Do you believe integrating AI into clinical cancer research will improve patient treatment outcomes?
